Last reviewed · How we verify
SHR-A1811；Albumin paclitaxel
At a glance
| Generic name | SHR-A1811；Albumin paclitaxel |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis (PHASE2)
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (PHASE2)
- This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy. (PHASE2)
- SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC (PHASE2)
- SNF Platform Study of HR+/ HER2-advanced Breast Cancer (PHASE2)
- A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-A1811；Albumin paclitaxel CI brief — competitive landscape report
- SHR-A1811；Albumin paclitaxel updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI